Unity Biotechnology, Inc. financial data

Symbol
UBX on Nasdaq
Location
285 East Grand Avenue, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - Apr 22, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 301 % -32.9%
Debt-to-equity 320 % +122%
Return On Equity -274 % -105%
Return On Assets -65.2 % -19.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.2M shares +2.54%
Common Stock, Shares, Outstanding 17.2M shares +2.54%
Entity Public Float 22.5M USD -34%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 16.9M shares +0.51%
Weighted Average Number of Shares Outstanding, Diluted 16.9M shares +0.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 12.1M USD -33.2%
General and Administrative Expense 15.7M USD -13%
Operating Income (Loss) -30.5M USD +27%
Net Income (Loss) Attributable to Parent -27.5M USD +31.9%
Earnings Per Share, Basic -2 USD/shares +39%
Earnings Per Share, Diluted -2 USD/shares +39%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8M USD +7.66%
Marketable Securities, Current 8.93M USD -69.1%
Assets, Current 17.6M USD -54.2%
Property, Plant and Equipment, Net 3.28M USD -32.4%
Operating Lease, Right-of-Use Asset 8.46M USD -32%
Other Assets, Noncurrent 71K USD -65.2%
Assets 30.3M USD -48.4%
Accounts Payable, Current 1.76M USD +26%
Accrued Liabilities, Current 6.06M USD +17.1%
Liabilities, Current 9.07M USD +17.3%
Operating Lease, Liability, Noncurrent 18.7M USD -17.4%
Liabilities 30.6M USD -12.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -518M USD -5.61%
Stockholders' Equity Attributable to Parent -205K USD -101%
Liabilities and Equity 30.3M USD -48.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.36M USD -22.7%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 6.78M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 17.2M shares +2.54%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 419K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.9M USD +6.83%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 118M USD +7.42%
Deferred Tax Assets, Gross 121M USD +5.99%
Operating Lease, Liability 22.6M USD -13.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.5M USD +31.8%
Lessee, Operating Lease, Liability, to be Paid 26M USD -16.1%
Property, Plant and Equipment, Gross 12.7M USD -11.5%
Operating Lease, Liability, Current 3.93M USD +10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.46M USD +3.22%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.29M USD +3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.42M USD -29.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.63M USD +3.23%
Deferred Tax Assets, Operating Loss Carryforwards 88.8M USD +9.55%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 17.5M USD +0.19%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.8M USD +2.98%
Operating Lease, Payments 1.28M USD +3.23%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 178K USD -21.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.19M USD -51.9%
Interest Expense 1.45M USD -61.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%